Applied Materials Commits $5 Billion to India as Chip Manufacturing Expands

Applied Materials, Inc. (NASDAQ:AMAT) plans to invest $5 billion in India over the next decade, expanding its research, supply-chain, and workforce capabilities as India tries to establish itself as a major semiconductor manufacturing hub.

The announcement came at SEMICON India, where more than 600 companies from 52 countries participated. India has committed more than $21 billion in semiconductor incentives and expects domestic semiconductor consumption to reach $110 billion by 2030. Applied’s investment is therefore aimed at building a longer-term presence in an emerging semiconductor ecosystem rather than generating an immediate revenue contribution.

India Investment Could Expand Applied Materials’ Long-Term Growth

The investment could give Applied Materials, Inc. an early position in a market that is attempting to diversify semiconductor production beyond established hubs such as China and Taiwan. India has already approved 12 semiconductor projects under its incentive program, while commercial production has begun at some chip-packaging facilities. As more fabs and packaging facilities become operational, Applied could capture demand for deposition, etch, inspection, packaging, and other process equipment. Its existing portfolio spans these manufacturing stages, giving the company multiple opportunities to participate as India’s ecosystem develops.

The investment also fits Applied’s current growth cycle. In fiscal Q3 2026, revenue reached a record $9.12 billion, up 25% year over year, while gross margin rose to 50.3% and operating income increased to $3.08 billion. Applied generated a record $3.04 billion in operating cash flow during the quarter. The company has said strong AI-driven demand is supporting leading-edge logic, DRAM and advanced packaging, while it expects semiconductor-equipment growth to remain strong through 2027. A larger Indian R&D and supply-chain footprint could therefore support capacity and customer diversification as semiconductor investment expands globally.

Applied Materials Faces Execution Risks With Its India Expansion

The biggest risk is that India’s semiconductor ambitions may take considerably longer to translate into equipment revenue. Reuters reported that India still has no large-scale chip fabrication facility in commercial production, while Tata Electronics’ planned $10 billion fab in Gujarat has been delayed by nearly two years. That means Applied Materials, Inc. could commit substantial capital well before the local customer base generates meaningful equipment demand. The $5 billion commitment spread over ten years also represents a long-duration capital allocation rather than an immediate earnings catalyst.

The investment could also pressure returns if India’s manufacturing buildout progresses more slowly than expected. Applied already faces significant geopolitical exposure: its SEC filing says export restrictions have limited its China market and increased exposure to Chinese competitors. The company also paid $253 million in 2026 to settle a U.S. Commerce Department inquiry involving certain China shipments. At the same time, investors have questioned whether Applied can maintain its recent growth and margins; Reuters noted that its fourth-quarter revenue forecast of $10.25 billion came with a roughly 50.4% margin outlook amid increasing competition. Expanding in India could diversify geopolitical exposure, but it does not eliminate execution, regulatory, or capital-allocation risks.

Conclusion

Applied Materials, Inc.’s $5 billion India commitment strengthens its long-term positioning in a market targeting $110 billion of semiconductor consumption by 2030, while aligning with the company’s need to expand capacity as AI drives demand for advanced chips and packaging. The main limitation is timing: India’s fab ecosystem remains immature, with major projects still facing delays. Consequently, the investment is more directly relevant to Applied’s long-term geographic diversification and competitive positioning than to near-term revenue or earnings.

READ NEXT: Lockheed Martin Fast-Tracks Secret Missile as Global Weapons Demand Rises and AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England

This article is originally published at Insider Monkey.